{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:47:31Z","timestamp":1792450051740,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.lungcan.2021.10.019","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T01:33:36Z","timestamp":1636162416000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The highlights of the 15th international conference of the international mesothelioma interest group \u2013 Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?"],"prefix":"10.1016","volume":"163","author":[{"given":"Sonja","family":"Klebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Brcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"I. Chen-Yost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Jaurand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.10.019_b0005","series-title":"15th International Conference of the International Mesothelioma Interest Group (iMig), Brisbane, Australia","author":"Armato","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0010","series-title":"Thoracic Tumors","author":"WHO Classification of Tumors","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0015","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"Is MTAP expression an adequate surrogate of CDKN2A (p16) homozygous deletion ? Cross-validation from the experience of the MESOPATH Reference Center","author":"Brcic","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0020","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"Differential diagnosis of biphasic malignant pleural mesothelioma on pleural effusions by gene expression","author":"Bruno","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0025","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"Histologic differences between germline and non-germline mutated mesotheliomas,","author":"Chen-Yost","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0030","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"As pathologist what have we learned from deep learning for the diagnostic or pronostic of mesothelioma","author":"Galateau-Salle","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0035","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"Mesothelioma in situ","author":"Klebe","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0040","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"Case Series Exploration of Early Mesothelioma in Pleural effusions: The Significance of BAP1 Immunohistochemistry and CDKN2A\/p16 Fluorescence in Situ Hybridisation","author":"Louw","year":"2021"},{"key":"10.1016\/j.lungcan.2021.10.019_b0045","doi-asserted-by":"crossref","first-page":"934","DOI":"10.21037\/tlcr-2019-pps-10","article-title":"Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma","volume":"9","author":"Hjerpe","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2021.10.019_b0050","first-page":"899","article-title":"Malignant mesothelioma in situ: Clinical and pathologic implications","volume":"15","author":"Churg","year":"2020","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2021.10.019_b0055","first-page":"446","article-title":"The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis","volume":"53","author":"Klebe","year":"2021","journal-title":"Pathology (Phila)"},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.019_b0060","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.lungcan.2021.10.019_b0065","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/his.13872","article-title":"Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma","volume":"75","author":"Hamasaki","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2021.10.019_b0075","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2021.10.019_b0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2021.10.019_b0085","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2021.10.019_b0090","doi-asserted-by":"crossref","first-page":"152377","DOI":"10.1016\/j.prp.2019.03.006","article-title":"The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?","volume":"215","author":"Kulduk","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.lungcan.2021.10.019_b0095","series-title":"GeneReviews(\u00ae), Seattle (WA)","article-title":"BAP1 Tumor predisposition syndrome","author":"Pilarski","year":"1993"},{"issue":"4","key":"10.1016\/j.lungcan.2021.10.019_b0100","first-page":"565","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol. Oncol. Res. POR"},{"key":"10.1016\/j.lungcan.2021.10.019_b0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"28","key":"10.1016\/j.lungcan.2021.10.019_b0115","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2021.10.019_b0120","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.lungcan.2021.10.019_b0130","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel","year":"2020","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.10.019_b0135","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2021.10.019_b0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5858\/arpa.2017-0307-OA","article-title":"Malignant mesothelioma in individuals with nonmesothelial neoplasms","volume":"142","author":"Butnor","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.lungcan.2021.10.019_b0145","series-title":"15th Meeting of the International Mesothelioma Interest Group, Brisbane, Australia","article-title":"Multiple cancers in 416 patients with malignant mesothelioma","author":"Panou","year":"2021"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0150","first-page":"29","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: Towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.lungcan.2021.10.019_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: Does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000377697","volume":"59","author":"Hjerpe","year":"2015","journal-title":"Acta Cytol."},{"issue":"8","key":"10.1016\/j.lungcan.2021.10.019_b0170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5858\/arpa.2018-0020-RA","article-title":"Cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Ten years of clinical experience in relation to international guidelines","volume":"142","author":"Hjerpe","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.019_b0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch. Int. J. Pathol."},{"issue":"12","key":"10.1016\/j.lungcan.2021.10.019_b0180","first-page":"939","article-title":"Testing for BAP1 loss and CDKN2A\/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology","volume":"128","author":"Chevrier","year":"2020","journal-title":"CancerCytopathol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.019_b0185","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.18632\/oncotarget.13174","article-title":"Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis","volume":"8","author":"Bruno","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lungcan.2021.10.019_b0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jmoldx.2019.12.009","article-title":"Differential diagnosis of malignant pleural mesothelioma on cytology: A gene expression panel versus BRCA1-associated protein 1 and p16 tests","volume":"22","author":"Bruno","year":"2020","journal-title":"J. Mol. Diagn. JMD"},{"issue":"4","key":"10.1016\/j.lungcan.2021.10.019_b0195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jmoldx.2019.12.009","article-title":"Differential diagnosis of malignant pleural mesothelioma on cytology","volume":"22","author":"Bruno","year":"2020","journal-title":"J. Mol. Diagn."},{"issue":"9","key":"10.1016\/j.lungcan.2021.10.019_b0200","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","article-title":"Bap1 Is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations","volume":"76","author":"Kadariya","year":"2016","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.lungcan.2021.10.019_b0205","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1016\/j.cub.2017.09.007","article-title":"Long-Fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a (Ink4a\/Arf)","volume":"27","author":"Chernova","year":"2017","journal-title":"Curr. Biol. CB"},{"issue":"8","key":"10.1016\/j.lungcan.2021.10.019_b0210","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/ijms19082191","article-title":"Mesotheliomas in genetically engineered mice unravel mechanism of mesothelial carcinogenesis","volume":"19","author":"Jean","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.019_b0215","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","article-title":"Roles and mechanisms of BAP1 deubiquitinase in tumor suppression","volume":"28","author":"Masclef","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.lungcan.2021.10.019_b0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41420-021-00406-2","article-title":"Emerging multifaceted roles of BAP1 complexes in biological processes","volume":"7","author":"Szczepanski","year":"2021","journal-title":"Cell Death Discov."},{"issue":"17","key":"10.1016\/j.lungcan.2021.10.019_b0225","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1016\/j.molcel.2021.06.020","article-title":"BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation","volume":"81","author":"Conway","year":"2021","journal-title":"Mol. Cell"},{"issue":"22","key":"10.1016\/j.lungcan.2021.10.019_b0230","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1158\/0008-5472.CAN-14-0221","article-title":"Deubiquitination of \u03b3-tubulin by BAP1 prevents chromosome instability in breast cancer cells","volume":"74","author":"Zarrizi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2021.10.019_b0235","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","article-title":"BAP1 regulates different mechanisms of cell death","volume":"9","author":"Affar","year":"2018","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.lungcan.2021.10.019_b0240","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/biom10030446","article-title":"Methylation of the suppressor gene p16INK4a: Mechanism and consequences","volume":"10","author":"Tramontano","year":"2020","journal-title":"Biomolecules"},{"issue":"25","key":"10.1016\/j.lungcan.2021.10.019_b0245","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1021\/bi200642e","article-title":"Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer","volume":"50","author":"Li","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.lungcan.2021.10.019_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678447","article-title":"CDKN2A determines mesothelioma cell fate to EZH2 inhibition","volume":"11","author":"Pinton","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2021.10.019_b0255","doi-asserted-by":"crossref","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: Not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat. Rev."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T23:44:41Z","timestamp":1717544681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0169500221005900"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.10.019","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The highlights of the 15th international conference of the international mesothelioma interest group \u2013 Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}